PTEO Proteo Inc (GM)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 5, 2014

 

PROTEO, INC.

 

(Exact name of registrant as specified in its charter)

 

Nevada		000-30728		88-0292249
(State of other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
2102 Business Center Drive, Irvine, California 92612
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (949) 253-4155
Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o    Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On December 5, 2014, Proteo, Inc. (the “Company”) announced that Dr. Juergen Paal was appointed as the Chief Operating Officer of Proteo Biotech AG, the Company’s wholly owned subsidiary, effective December 1, 2014. He will be responsible for Proteo's clinical development program, product launch preparation, business development and partnering initiatives.

 

Dr. Paal, who is 43 years old, has been a member of the scientific advisory board of Proteo Biotech AG since March 2006 and has more than 13 years’ experience in research and development, corporate strategic management and business development. From October 2012 to December 2014, Dr. Paal served as director business development therapeutic apheresis at Fresenius Medical Care. From May 2010 to September 2012, Dr. Paal was heading the strategic coordination office of Fresenius Medical Care EMEALA. From November 2007 to April 2010 Dr. Paal served as manager international strategic development at Fresenius Medical Care. Before he worked for 5 years at Altana Pharma AG in Research and Development and Strategy Development.

 

A copy of the press release announcing Dr. Paal’s appointment is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by this reference.

 

 

Item 9.01     Financial Statements and Exhibits.

 

	(d)     Exhibits.
	Exhibit No.	Description
	99.1	Press Release dated December 5, 2014

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	PROTEO, INC.
Date: December 11, 2014	By:	/s/ BIRGE BARGMANN
		Birge Bargmann Chief Executive Officer

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit
Number	Description
99.1	Press Release dated December 5, 2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 99.1

 

Proteo Biotech AG Expands Management Board

2014-12-05

IRVINE, CA & KIEL, Germany - Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced that the company strengthens its Management Board. The Supervisory Board of Proteo Biotech AG has appointed Dr. Juergen Paal as a new member of the company’s Management Board, effective from Dec 1st, 2014. In this leadership role as Proteo Biotech AG's new Chief Operating Officer, he will be responsible for Proteo's clinical development program, product launch preparation, business development and partnering initiatives.

This appointment follows Dr. Paal's involvement with Proteo Biotech AG since 2006 when he joined the scientific advisory board. Dr. Paal has worked in two major international health care companies where he has acquired more than 13 years of experience in research and development, corporate strategic management and business development. Dr. Paal joins from Fresenius Medical Care, where he held a director's position with responsibility for business development in therapeutic apheresis.

"We welcome Juergen to the Management Board. We have profited greatly from Juergen's contributions in his former advisory role for Proteo, and together with his international working experience in leading positions in the health care industry, his appointment to the Management Board represents an important cornerstone in the preparation for the commercialization of Elafin" said Birge Bargmann, Chief Executive Officer, and Oliver Wiedow, Chairman of the Supervisory Board..

Dr. Paal commented: "It is an exciting moment to join Proteo Biotech AG at this advanced stage of the clinical development of the company's drug candidate Elafin after the drug has shown promising results in phase I and phase II clinical trials. The major focus is now on the pivotal clinical trial with Elafin in its lead indication, and the exploration of partnering opportunities for the marketing and distribution of Elafin to exploit the full commercial potentials of this promising product."

About Proteo

Proteo, Inc. is a Nevada corporation and has one wholly owned subsidiary, Proteo Biotech AG, a German corporation. The Company is a clinical stage drug development company focusing on the development of anti-inflammatory treatments for rare diseases with significant unmet needs (www.proteo.de).

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward looking statements and risks and uncertainties involved are further qualified by other factors including, but not limited to those set forth in the company’s Form 10-K filing and other filings with the United States Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.